BioSpace News Archive

CardioNXT announced today that it received marketing clearance from the U.S. Food and Drug Administration (FDA) for the platform technology comprised of the iMap 3D Navigation & Mapping System ™ , Activate Software ™ , Sensor Enabled Axis Patient Patches ™ , and MultiLink Sensor Enabled Catheter ™ .

MicroConstants, Inc., a leader in bioanalytical testing services, announced that it has signed an agreement with BioAgilytix Labs, a leading global contract research organization (CRO) focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development.

Ginkgo Bioworks today announced a revenue and business update for the first half of 2021.

Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for NUZYRA ® (omadacycline) for the treatment of infections caused by Nontuberculous Mycobacteria (NTM).

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today releases details of two ancillary studies under the ProstACT program that significantly extend the evaluation of Telix’s TLX591 antibody-directed 177Lu (lutetium) therapeutic platform into areas of unmet medical need across the full prostate cancer treatment journey.

Eve & Co Incorporated (“Eve & Co”, “we”, “us” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF), through its wholly-owned subsidiary, Natural MedCo Ltd. (“NMC”) is pleased to announce that it has made gross revenues of $4.0 million in the first six months of 2021, successfully surpassing its gross revenues of $3.8 million for the entire 2020 financial year.

Jardiance® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

American Bio Medica Corporation (OTCQB:ABMC) today announced financial results for the three and six months ended June 30, 2021.

BioAgilytix Labs, LLC announced today that it signed a definitive agreement to acquire MicroConstants, adding it to its family of companies.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, is pleased to highlight positive results from an independent analysis of standard surgical risk patients undergoing carotid endarterectomy and transcarotid artery revascularization for atherosclerotic carotid disease.